Cargando…
A Phase II Trial of Adjuvant Durvalumab Following Trimodality Therapy for Locally Advanced Esophageal and Gastroesophageal Junction Adenocarcinoma: A Big Ten Cancer Research Consortium Study
BACKGROUND: Most patients with resectable locally advanced esophageal and gastroesophageal junction (GEJ) adenocarcinoma (AC) receive concurrent chemoradiation (CRT) followed by esophagectomy. The majority of patients do not achieve pathologic complete response (pCR) with neoadjuvant CRT, and the re...
Autores principales: | Mamdani, Hirva, Schneider, Bryan, Perkins, Susan M., Burney, Heather N., Kasi, Pashtoon Murtaza, Abushahin, Laith I., Birdas, Thomas, Kesler, Kenneth, Watkins, Tracy M., Badve, Sunil S., Radovich, Milan, Jalal, Shadia I. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8484871/ https://www.ncbi.nlm.nih.gov/pubmed/34604072 http://dx.doi.org/10.3389/fonc.2021.736620 |
Ejemplares similares
-
Spotlight on the treatment of ALK-rearranged non-small-cell lung cancer
por: Mamdani, Hirva, et al.
Publicado: (2017) -
Histone Deacetylase Inhibition in Non-small Cell Lung Cancer: Hype or Hope?
por: Mamdani, Hirva, et al.
Publicado: (2020) -
Immunotherapy in Lung Cancer: Current Landscape and Future Directions
por: Mamdani, Hirva, et al.
Publicado: (2022) -
Gastroesophageal junction adenocarcinoma displays abnormalities in homologous recombination and nucleotide excision repair
por: Dewalt, Robin I, et al.
Publicado: (2014) -
Trimodality treatment in gastric and gastroesophageal junction cancers: Current approach and future perspectives
por: Charalampakis, Nikolaos, et al.
Publicado: (2022)